Growth Metrics

West Pharmaceutical Services (WST) Cost of Revenue (2016 - 2026)

West Pharmaceutical Services has reported Cost of Revenue over the past 18 years, most recently at $548.5 million for Q1 2026.

  • Quarterly Cost of Revenue rose 17.68% to $548.5 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $2.1 billion through Mar 2026, up 8.28% year-over-year, with the annual reading at $2.0 billion for FY2025, 3.98% up from the prior year.
  • Cost of Revenue was $548.5 million for Q1 2026 at West Pharmaceutical Services, up from $501.1 million in the prior quarter.
  • Over five years, Cost of Revenue peaked at $548.5 million in Q1 2026 and troughed at $418.9 million in Q3 2022.
  • The 5-year median for Cost of Revenue is $465.2 million (2024), against an average of $469.7 million.
  • Biggest five-year swings in Cost of Revenue: increased 0.14% in 2022 and later increased 17.68% in 2026.
  • Tracing WST's Cost of Revenue over 5 years: stood at $446.6 million in 2022, then increased by 1.61% to $453.8 million in 2023, then increased by 4.72% to $475.2 million in 2024, then grew by 5.45% to $501.1 million in 2025, then grew by 9.46% to $548.5 million in 2026.
  • According to Business Quant data, Cost of Revenue over the past three periods came in at $548.5 million, $501.1 million, and $510.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.